-transparent.png){kind=logo}
Twenty-two patients with advanced haemopoietic and other malignancies were treated intramuscularly with recombinant interferon-alpha 2C in a daily escalating dose. The most common side-effects were flu-like symptoms. Two patients showed severe neurotoxicity, which was completely reversible in 1 case. Doses above 30 X 10(6) IU/day were poorly tolerated and could only be achieved in a minority of the patients. Objective tumour responses were documented in malignant lymphomas, hairy cell leukaemia, and renal cell carcinoma.
Related Publications
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
January 1988,
Molecular biotherapy,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
January 1983,
Journal of biological response modifiers,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
January 1992,
International journal of STD & AIDS,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
January 1981,
Haematology and blood transfusion,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
November 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
March 1985,
Gan to kagaku ryoho. Cancer & chemotherapy,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
June 1990,
Molecular biotherapy,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
November 1992,
Cancer,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
January 2002,
Cancer biology & therapy,
J T Janssen, and
H Ludwig, and
W Scheithauer, and
B E de Pauw, and
A Keyser, and
R van Tol, and
R Flener
April 1987,
Journal of biological response modifiers,
